The company provides visual effects (VFX) services for films, television, and digital streaming platforms, specializing in computer-generated imagery and post-production for major entertainment studios.
The company operates in a highly competitive, labor-intensive industry where high ROCE is likely driven by low capital intensity rather than structural advantages, as evidenced by the lack of pricing power and negative cash conversion.
Capital has been primarily directed toward bonus share issuances and an IPO to fund expansion, though the negative cash conversion suggests that reinvestment is not yet translating into liquid shareholder value.
The business collapsed as the massive gap between accounting profits and actual cash flow became an unbridgeable chasm. While revenue appeared to grow, the company was essentially financing its own customers through ballooning trade receivables that never converted to cash. The negative cash conversion ratio proved to be a terminal warning sign rather than a temporary glitch. As the labor-intensive model required more headcount to service low-margin contracts, the lack of pricing power led to a margin squeeze, and the 'intangible assets' on the balance sheet were revealed to be capitalized costs with no productive value, resulting in a total wipeout of shareholder equity.
RichFakir rates Identical Brains Studios Ltd's business quality as poor — 41/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Identical Brains Studios Ltd is trading about 31% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Identical Brains Studios Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Identical Brains Studios Ltd's fair value is about ₹24 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →